Amicus Therapeutics Inc. buy tamam
Start price
24.05.18
/
50%
€13.67
Target price
04.11.21
€23.00
Performance (%)
-22.43%
End price
05.11.21
€10.60
Summary
This prediction ended on 05.11.21 with a price of €10.60. The prediction for Amicus Therapeutics Inc. disappointed with a performance of -22.43%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Amicus Therapeutics Inc. | 3.883% | 3.883% | -6.957% | 20.225% |
iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by tamam for this prediction
In the thread Amicus Therapeutics Inc. diskutieren
Amicus verfügt über eine Entwicklungspipeline mit neuartigen „First-in-Class-Behandlungen“
The firm has one of the best management teams (especially CEO John Crowley) of the companies on my radar, a near term regulatory update for their Pompe program could move the stock significantly in the event of accelerated approval pathway, the Galafold launch (and possible approval in the US) are also upside drivers and after their February secondary offering they have a comfortable cash position.
Kursziel geändert auf 19,766
Kursziel geändert auf 13,766
Kursziel geändert auf 16,0
Kursziel geändert auf 23,0
In the thread Trading Amicus Therapeutics Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten